Trevi Therapeutics Inc (TRVI)

Dec 11, 2025

Trevi Therapeutics stock hits all-time high of 14.01 USD By Investing.com - Investing.com Nigeria

Dec 11, 2025

Dec 11, 2025

Marshall Wace LLP Has $13.55 Million Stock Position in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Dec 11, 2025

Dec 11, 2025

Trevi Therapeutics Stock Surges to Record High on Clinical and Strategic Momentum - AD HOC NEWS

Dec 11, 2025

Dec 11, 2025

Trevi Therapeutics (NASDAQ:TRVI) Hits New 12-Month HighTime to Buy? - MarketBeat

Dec 11, 2025

Dec 10, 2025

Trevi Therapeutics (NASDAQ:TRVI) Trading 5.7% HigherTime to Buy? - MarketBeat

Dec 10, 2025

Dec 10, 2025

Trevi Therapeutics stock hits all-time high of 14.01 USD - Investing.com

Dec 10, 2025

Dec 09, 2025

Trevi Therapeutics, Inc. $TRVI Shares Acquired by Vivo Capital LLC - MarketBeat

Dec 09, 2025

Dec 07, 2025

226,381 Shares in Trevi Therapeutics, Inc. $TRVI Bought by Prudential Financial Inc. - MarketBeat

Dec 07, 2025

Dec 06, 2025

Trevi Therapeutics Appoints New Chief Financial Officer - The Globe and Mail

Dec 06, 2025

Dec 06, 2025

Affinity Asset Advisors LLC Raises Holdings in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Dec 06, 2025

Dec 05, 2025

Trevi Therapeutics appoints David Hastings as chief financial officer By Investing.com - Investing.com Nigeria

Dec 05, 2025

Dec 05, 2025

Trevi Therapeutics, Inc. Announces Appointment of David Hastings as Chief Financial Officer, Effective January 6, 2026 - marketscreener.com

Dec 05, 2025

Dec 05, 2025

Trevi Therapeutics, Inc. Announces the Hiring of David Hastings to Serve as the Company?s Principal Financial Officer, Effective January 6, 2026 - marketscreener.com

Dec 05, 2025

Dec 05, 2025

New Haven biotech names new CFO - Hartford Business Journal

Dec 05, 2025

Dec 05, 2025

Trevi Therapeutics appoints David Hastings as chief financial officer - Investing.com

Dec 05, 2025

Dec 05, 2025

Trevi Therapeutics, Inc. $TRVI Shares Purchased by Geode Capital Management LLC - MarketBeat

Dec 05, 2025

Dec 05, 2025

Trevi Therapeutics appoints David Hastings as new CFO By Investing.com - Investing.com Nigeria

Dec 05, 2025

Dec 04, 2025

Trevi Therapeutics Taps David Hastings as CFO - Contract Pharma

Dec 04, 2025

Dec 04, 2025

Trevi Therapeutics appoints David Hastings as new CFO - Investing.com India

Dec 04, 2025

Dec 04, 2025

Trevi Therapeutics, Inc. $TRVI Shares Purchased by Panagora Asset Management Inc. - MarketBeat

Dec 04, 2025

Dec 04, 2025

Trevi Therapeutics Names David Hastings CFO - marketscreener.com

Dec 04, 2025

Dec 04, 2025

Trevi Therapeutics announces appointment of David Hastings as chief financial officer - marketscreener.com

Dec 04, 2025

Dec 04, 2025

Trevi Therapeutics Announces Appointment Of David Hastings As Chief Financial Officer - TradingView — Track All Markets

Dec 04, 2025

Dec 04, 2025

Trevi Therapeutics Announces Appointment of David Hastings as Chief Financial Officer - cnhinews.com

Dec 04, 2025

Dec 03, 2025

Trevi Therapeutics: "Buy" Rating For Haduvio Treating Chronic Cough In IPF And Beyond - Seeking Alpha

Dec 03, 2025

Dec 03, 2025

Trevi Therapeutics stock hits all-time high at 13.92 USD By Investing.com - Investing.com Canada

Dec 03, 2025

Dec 03, 2025

Trevi Therapeutics stock hits all-time high at 13.92 USD - Investing.com

Dec 03, 2025

Dec 02, 2025

Trevi Therapeutics (TRVI) Rises on Takeover Speculation - GuruFocus

Dec 02, 2025

Dec 02, 2025

Trevi Therapeutics edges higher amid takeover speculation - MSN

Dec 02, 2025

Dec 02, 2025

Trevi Therapeutics edges higher amid takeover speculation (TRVI:NASDAQ) - Seeking Alpha

Dec 02, 2025

Dec 02, 2025

Trevi Therapeutics (TRVI) Stock Analysis Report | Financials & Insights - Benzinga

Dec 02, 2025

Nov 30, 2025

Jefferies Financial Group Inc. Makes New Investment in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Nov 30, 2025

Nov 30, 2025

Trevi Therapeutics Inc Strengthens Strategy For Clinical Design - Kalkine Media

Nov 30, 2025

Nov 29, 2025

Tejara Capital Ltd Purchases 146,879 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat

Nov 29, 2025

Nov 27, 2025

Trevi Therapeutics (NASDAQ:TRVI) Sets New 52-Week HighStill a Buy? - MarketBeat

Nov 27, 2025

Nov 26, 2025

Stocks of Trevi Therapeutics Inc (TRVI) are poised to climb above their peers - Setenews

Nov 26, 2025

Nov 26, 2025

Trevi Therapeutics stock hits all-time high at 12.31 USD By Investing.com - Investing.com India

Nov 26, 2025

Nov 26, 2025

Trevi Therapeutics stock hits all-time high at 12.31 USD - Investing.com

Nov 26, 2025

Nov 26, 2025

AXQ Capital LP Invests $227,000 in Trevi Therapeutics, Inc. $TRVI - MarketBeat

Nov 26, 2025

Nov 25, 2025

Trevi Therapeutics’ Earnings Call Highlights Promising Outlook - MSN

Nov 25, 2025

Nov 24, 2025

The Bull Case For Trevi Therapeutics (TRVI) Could Change Following Narrowed Losses and New Shelf Registration - simplywall.st

Nov 24, 2025

Nov 24, 2025

Chronic Refractory Cough Market is Expected to Boom by 2034 Driven by Advancements in Treatment Options | DelveInsight - GlobeNewswire Inc.

Nov 24, 2025

Nov 24, 2025

MAI Capital Management Sells 537,497 Shares of Trevi Therapeutics, Inc. $TRVI - MarketBeat

Nov 24, 2025

Nov 23, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Average Rating of "Buy" by Analysts - MarketBeat

Nov 23, 2025

Nov 22, 2025

Leerink Partnrs Has Bullish Outlook for TRVI FY2025 Earnings - MarketBeat

Nov 22, 2025

Nov 21, 2025

B. Riley Increases Earnings Estimates for Trevi Therapeutics - MarketBeat

Nov 21, 2025